Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ACP3 | P15309 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28238546 | 0.72 | LMNA (0.46) | TRPM8LMNAAOC3TP53MAPT | |
| SCHEMBL11141579 | 0.71 | LMNA (0.47) | TRPM8LMNAAOC3TP53MAPT | |
| SCHEMBL1031859 | 0.68 | LMNA (0.52) | TRPM8LMNAAOC3POLBMEN1 | |
| Bromide SCHEMBL4071099 | 0.68 | HTR2A (0.46) | TRPM8LMNAAOC3MEN1KMT2A | |
| SCHEMBL8576434 | 0.68 | LMNA (0.52) | TRPM8LMNAAOC3POLBMEN1 | |
| SCHEMBL26638387 | 0.67 | TRPM8 (0.47) | TRPM8LMNAAOC3POLBMEN1 | |
| SCHEMBL394801 | 0.67 | KCNA5 (0.47) | TP53MEN1HTTKMT2AALDH1A1 | |
| Bromide SCHEMBL6625831 | 0.66 | MEN1 (0.45) | TRPM8LMNAAOC3TP53MAPT | |
| Phosphoric Acid SCHEMBL9105394 | 0.66 | LMNA (0.50) | SRCLMNAAOC3POLBACP3 | |
| SCHEMBL1542690 | 0.66 | SRC (0.50) | SRCLMNAPOLBACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058210-B2 | Arylphenyl-substituted cyclic keto-enols | BAYER CROPSCIENCE AG (DE) | 2011-11-15 | — | — | US | disclosed |
| US-20100087320-A1 | ARYLPHENYL-SUBSTITUTED CYCLIC KETO-ENOLS | LIEB FOLKER | 2010-04-08 | — | — | US | disclosed |
| US-6221862-B1 | Microbicide 1,4,2-dioxazine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2001-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087320-A1 | ARYLPHENYL-SUBSTITUTED CYCLIC KETO-ENOLS | KCNE1, DDT, KCNQ3 | SRC 860/4885TRPM8 4673/4885LMNA 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.